References

Vaccine trial end dates and exclusion criteria:

Pfizer

“Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals”

*Exclusion Criteria*:

“Women who are pregnant or breastfeeding.”

Actual Study Completion Date:

* February 10, 2023 *

https://clinicaltrials.gov/ct2/show/NCT04368728

Moderna

“A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19”

*Exclusion Criteria:*

“Is pregnant or breastfeeding.”

Actual Study Completion Date:

*December 29, 2022*

https://clinicaltrials.gov/ct2/show/study/NCT04470427

AstraZeneca

“A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19”

Estimated Study Completion Date:

*February 24, 2023*

https://clinicaltrials.gov/ct2/show/NCT04516746

[Under-40s are offered an alternative to AstraZeneca in the UK https://www.forbes.com/sites/melissaholzberg/2021/05/07/heres-why-the-uk-is-offering-under-40s-alternatives-to-the-astrazeneca-covid-19-vaccine/?sh=285925614471]

Janssen

“A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE)”

Estimated Study Completion Date:

*March 31, 2023*

https://clinicaltrials.gov/ct2/show/study/NCT04505722

“All participants of childbearing potential must: have a negative highly sensitive urine pregnancy test at screening; and have a negative highly sensitive urine pregnancy test immediately prior to each study vaccine administration.”

Novavax

“This is a phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants and adolescent participants.”

Exclusion Criteria:

“Participants who are breastfeeding, pregnant, or who plan to become pregnant within 3 months following last study vaccination.”

Estimated Study Completion Date:

*June 30, 2023*

https://clinicaltrials.gov/ct2/show/results/NCT04611802

Pfizer trial on pregnant women:

https://maryannedemasi.substack.com/p/exclusive-whatever-happened-to-pfizers

https://clinicaltrials.gov/ct2/show/NCT04754594

Vaccine ingredients leave injection site:

https://www.docdroid.net/xq0Z8B0/pfizer-report-japanese-government-pdf#page=17

https://childrenshealthdefense.org/defender/covid-vaccine-spike-protein-travels-from-injection-site-organ-damage/

https://doctors4covidethics.org/wp-content/uploads/2021/07/Pfizer-pharmacokinetics-and-toxicity.pdf

Safety signals and menstrual changes:

VAERS: https://www.openvaers.com/covid-data

UK Yellow Card: https://yellowcard.ukcolumn.org/yellow-card-reports

“It is estimated that only 10% of serious reactions and between 2 and 4% of non-serious reactions are reported.”

https://www.gov.uk/drug-safety-update/yellow-card-please-help-to-reverse-the-decline-in-reporting-of-suspected-adverse-drug-reactions

“Pregnancy and menstrual abnormalities are significantly more frequent following COVID-19 vaccinations than that of Influenza vaccinations. A worldwide moratorium on the use of COVID-19 vaccines in pregnancy is advised until randomized prospective trials document safety in pregnancy and long-term follow-up in offspring.”

https://www.preprints.org/manuscript/202209.0430/v1

https://rescue.substack.com/p/deep-in-the-wombs-of-women-the-hidden

https://worldcouncilforhealth.org/multimedia/dr-jessica-rose-fertility-vaers/